

Study Design Schematic
Screening
•CLBP
•≤60 mg oral morphine/day
•Pain intensity (PI) score ≥5
4-week, Open Label
Titration Period
A, 2xA, 3xA, 4xA mcg; bid
PI score ≤4
Placebo
Randomized,
Double Blind
Treatment Period
Day 84
End of Study
BEMA Buprenorphine
PI score >4
Not tolerated
Discontinued

Figure 1.



Subject Disposition
Titration (n=334)
Not treated 2
Discontinued intervention (n= 97)
Adverse event 37
Lack of efficacy 30
Non-compliance 10
Lost to follow-up 6
Other 14
Randomized (n=235)
BEMA Buprenorphine (n=117)
Placebo (n=118)
Discontinued intervention (n= 28)
Lack of efficacy 5
Adverse event 7
Withdrew consent 0
Non-compliance 5
Lost to follow-up 2
Other 9
Discontinued intervention (n=37)
Adverse event 6
Lack of efficacy 6
Withdrew consent 1
Non-compliance 5
Lost to follow-up 7
Other 12
Completed Study (n=89)
Completed Study (n=81)

Figure 2.



Mean Change from Baseline in Daily Pain Intensity
BEMA Buprenorphine Minus Placebo
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
-1.4
P=0.5
P=0.066
P=0.067
P=0.025
Total Population (n=235)
Without Low Dose* (n=174)
Opioid Experienced (n-80)
Opioid Experienced w/o Low Dose* (n=64)

Figure 3.